Medroxyprogesterone acetate treatment of abnormal uterine bleeding

Factors predicting satisfaction

Holly E. Richter, Lee A. Learman, Feng Lin, R. Edward Varner, Susan L. Hendrix, Robert L. Summitt, A. Eugene Washington

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: This study was undertaken to identify the determinants of patient satisfaction with a cyclic regimen of medroxyprogesterone acetate (MPA) for abnormal uterine bleeding. STUDY DESIGN: A prospective cohort study of 413 premenopausal women were treated for 3 to 5 months with oral MPA 10 to 20 mg per day for 10 to 14 days per month. We assessed satisfaction with and willingness to continue MPA. Baseline characteristics hypothesized to predict treatment satisfaction were entered into logistic regression analysis. RESULTS: Sixty-five percent of subjects (271) completed at least 3 months of MPA, 79% (215) filled out a satisfaction survey, and 57% (123) expressed satisfaction with MPA. Satisfaction was predicted by age 35 years or older (odds ratio [OR] 2.67, Cl 1.07-6.7), desire for uterine conservation (OR 1.36, Cl 1.11-1.66), perceived importance of stopping bleeding (OR 0.69, Cl 0.54-0.87), and tubal sterilization (OR 0.52, Cl 0.28-0.96). Neither bleeding history nor parity predicted MPA satisfaction. CONCLUSION: These findings underscore the importance of considering patient age, fertility status, attitudes about uterine conservation, and desire for definitive resolution of bleeding when deciding whether to use MPA versus other treatments for abnormal uterine bleeding.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume189
Issue number1
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Medroxyprogesterone Acetate
Uterine Hemorrhage
Odds Ratio
Hemorrhage
Therapeutics
Tubal Sterilization
Parity
Patient Satisfaction
Fertility
Cohort Studies
Logistic Models
Regression Analysis
Prospective Studies

Keywords

  • Abnormal uterine bleeding
  • Medroxyprogesterone acetate
  • Satisfaction

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Richter, H. E., Learman, L. A., Lin, F., Varner, R. E., Hendrix, S. L., Summitt, R. L., & Washington, A. E. (2003). Medroxyprogesterone acetate treatment of abnormal uterine bleeding: Factors predicting satisfaction. American Journal of Obstetrics and Gynecology, 189(1), 37-42. https://doi.org/10.1067/mob.2003.342

Medroxyprogesterone acetate treatment of abnormal uterine bleeding : Factors predicting satisfaction. / Richter, Holly E.; Learman, Lee A.; Lin, Feng; Varner, R. Edward; Hendrix, Susan L.; Summitt, Robert L.; Washington, A. Eugene.

In: American Journal of Obstetrics and Gynecology, Vol. 189, No. 1, 01.07.2003, p. 37-42.

Research output: Contribution to journalArticle

Richter, HE, Learman, LA, Lin, F, Varner, RE, Hendrix, SL, Summitt, RL & Washington, AE 2003, 'Medroxyprogesterone acetate treatment of abnormal uterine bleeding: Factors predicting satisfaction', American Journal of Obstetrics and Gynecology, vol. 189, no. 1, pp. 37-42. https://doi.org/10.1067/mob.2003.342
Richter, Holly E. ; Learman, Lee A. ; Lin, Feng ; Varner, R. Edward ; Hendrix, Susan L. ; Summitt, Robert L. ; Washington, A. Eugene. / Medroxyprogesterone acetate treatment of abnormal uterine bleeding : Factors predicting satisfaction. In: American Journal of Obstetrics and Gynecology. 2003 ; Vol. 189, No. 1. pp. 37-42.
@article{084f9367d34f4f8aba68199fe4b5cae5,
title = "Medroxyprogesterone acetate treatment of abnormal uterine bleeding: Factors predicting satisfaction",
abstract = "OBJECTIVE: This study was undertaken to identify the determinants of patient satisfaction with a cyclic regimen of medroxyprogesterone acetate (MPA) for abnormal uterine bleeding. STUDY DESIGN: A prospective cohort study of 413 premenopausal women were treated for 3 to 5 months with oral MPA 10 to 20 mg per day for 10 to 14 days per month. We assessed satisfaction with and willingness to continue MPA. Baseline characteristics hypothesized to predict treatment satisfaction were entered into logistic regression analysis. RESULTS: Sixty-five percent of subjects (271) completed at least 3 months of MPA, 79{\%} (215) filled out a satisfaction survey, and 57{\%} (123) expressed satisfaction with MPA. Satisfaction was predicted by age 35 years or older (odds ratio [OR] 2.67, Cl 1.07-6.7), desire for uterine conservation (OR 1.36, Cl 1.11-1.66), perceived importance of stopping bleeding (OR 0.69, Cl 0.54-0.87), and tubal sterilization (OR 0.52, Cl 0.28-0.96). Neither bleeding history nor parity predicted MPA satisfaction. CONCLUSION: These findings underscore the importance of considering patient age, fertility status, attitudes about uterine conservation, and desire for definitive resolution of bleeding when deciding whether to use MPA versus other treatments for abnormal uterine bleeding.",
keywords = "Abnormal uterine bleeding, Medroxyprogesterone acetate, Satisfaction",
author = "Richter, {Holly E.} and Learman, {Lee A.} and Feng Lin and Varner, {R. Edward} and Hendrix, {Susan L.} and Summitt, {Robert L.} and Washington, {A. Eugene}",
year = "2003",
month = "7",
day = "1",
doi = "10.1067/mob.2003.342",
language = "English (US)",
volume = "189",
pages = "37--42",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Medroxyprogesterone acetate treatment of abnormal uterine bleeding

T2 - Factors predicting satisfaction

AU - Richter, Holly E.

AU - Learman, Lee A.

AU - Lin, Feng

AU - Varner, R. Edward

AU - Hendrix, Susan L.

AU - Summitt, Robert L.

AU - Washington, A. Eugene

PY - 2003/7/1

Y1 - 2003/7/1

N2 - OBJECTIVE: This study was undertaken to identify the determinants of patient satisfaction with a cyclic regimen of medroxyprogesterone acetate (MPA) for abnormal uterine bleeding. STUDY DESIGN: A prospective cohort study of 413 premenopausal women were treated for 3 to 5 months with oral MPA 10 to 20 mg per day for 10 to 14 days per month. We assessed satisfaction with and willingness to continue MPA. Baseline characteristics hypothesized to predict treatment satisfaction were entered into logistic regression analysis. RESULTS: Sixty-five percent of subjects (271) completed at least 3 months of MPA, 79% (215) filled out a satisfaction survey, and 57% (123) expressed satisfaction with MPA. Satisfaction was predicted by age 35 years or older (odds ratio [OR] 2.67, Cl 1.07-6.7), desire for uterine conservation (OR 1.36, Cl 1.11-1.66), perceived importance of stopping bleeding (OR 0.69, Cl 0.54-0.87), and tubal sterilization (OR 0.52, Cl 0.28-0.96). Neither bleeding history nor parity predicted MPA satisfaction. CONCLUSION: These findings underscore the importance of considering patient age, fertility status, attitudes about uterine conservation, and desire for definitive resolution of bleeding when deciding whether to use MPA versus other treatments for abnormal uterine bleeding.

AB - OBJECTIVE: This study was undertaken to identify the determinants of patient satisfaction with a cyclic regimen of medroxyprogesterone acetate (MPA) for abnormal uterine bleeding. STUDY DESIGN: A prospective cohort study of 413 premenopausal women were treated for 3 to 5 months with oral MPA 10 to 20 mg per day for 10 to 14 days per month. We assessed satisfaction with and willingness to continue MPA. Baseline characteristics hypothesized to predict treatment satisfaction were entered into logistic regression analysis. RESULTS: Sixty-five percent of subjects (271) completed at least 3 months of MPA, 79% (215) filled out a satisfaction survey, and 57% (123) expressed satisfaction with MPA. Satisfaction was predicted by age 35 years or older (odds ratio [OR] 2.67, Cl 1.07-6.7), desire for uterine conservation (OR 1.36, Cl 1.11-1.66), perceived importance of stopping bleeding (OR 0.69, Cl 0.54-0.87), and tubal sterilization (OR 0.52, Cl 0.28-0.96). Neither bleeding history nor parity predicted MPA satisfaction. CONCLUSION: These findings underscore the importance of considering patient age, fertility status, attitudes about uterine conservation, and desire for definitive resolution of bleeding when deciding whether to use MPA versus other treatments for abnormal uterine bleeding.

KW - Abnormal uterine bleeding

KW - Medroxyprogesterone acetate

KW - Satisfaction

UR - http://www.scopus.com/inward/record.url?scp=0038336594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038336594&partnerID=8YFLogxK

U2 - 10.1067/mob.2003.342

DO - 10.1067/mob.2003.342

M3 - Article

VL - 189

SP - 37

EP - 42

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -